Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer

• Published in: BioMed research international 2021-04, Vol.2021, p.8811751-8
• Main Authors: Qu, Yanli, Wang, Huan, Liu, Hangyu, Sun, Xiaohu, Li, Ji, Yu, Hong
• Format: Article
• Language: English
• Subjects: Aged; AKT protein; Apoptosis; B7-H1 Antigen - blood; B7-H1 Antigen - metabolism; Cancer therapies; Carcinoma, Non-Small-Cell Lung - metabolism; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - radiotherapy; Care and treatment; Case-Control Studies; Cell receptors; Cellular signal transduction; Chemotherapy; Correlation; Development and progression; Disease; Drinking water; Enzyme-linked immunosorbent assay; Enzymes; Ethanol; Female; Health aspects; Humans; Hypoxia-inducible factor 1a; Immunology; Kinases; Lung - chemistry; Lung - pathology; Lung cancer; Lung cancer, Non-small cell; Lung Neoplasms - metabolism; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Lung Neoplasms - radiotherapy; Male; Medical prognosis; Middle Aged; Non-small cell lung carcinoma; Patient outcomes; Patients; PD-1 protein; PD-L1 protein; Programmed Cell Death 1 Receptor - blood; Programmed Cell Death 1 Receptor - metabolism; Protein biosynthesis; Protein kinases; Proteins; Radiation; Radiation therapy; Radiotherapy; Statistical analysis; Surgery; Survival; T cell receptors; TOR protein; Tumors
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2021/8811751

It is aimed at investigating the changes of serum soluble programmed death-ligand 1 (sPD-L1) expression level in nonsmall cell lung cancer (NSCLC) before and after radiotherapy, the correlation of PD-L1, PD-1, and proteins of Akt (protein kinase B), mTOR, and HIF-1α, and the molecular mechanism of the PD-1/PD-L1 pathway in the development of NSCLS. A total of 126 NSCLC patients receiving radiotherapy in Liaoning Cancer Hospital from September 2018 to September 2019 were selected as the observation group, and another 58 healthy volunteers were selected as the control group. NSCLC patients were divided into group A (stage I-II, stereotactic radiotherapy) and group B (stage III, intensity-modulated radiation therapy) according to the cancer stage. The efficacy of radiotherapy was evaluated, and sPD-L1 expression was detected by ELISA. The immunohistochemical staining was adopted to detect protein expressions of Akt, mTOR, and HIF-1α in NSCLC tissues. The correlation between their expression and expression of PD-L1 and PD-1 was analyzed. The results showed that the overall response rate (ORR) of group A was 89.29%, the clinical benefit response (CBR) was 96.43%, the median survival time (MST) was 25 months, and the survival rate within three years was 72.56%. In group B, the ORR was 70.41%, the CBR was 97.96%, the MST was 18 months, and the survival rate within three years was 34.67%. Comparison of overall serum sPD-L1 expression in the control group, group A, and group B and between groups before radiotherapy was statistically significant (P